Inventurus Knowledge Solutions Limited (IKS) Fair Value & Analysis
Healthcare · IN · Market cap ₹308B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated yesterday
Share price +9.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,259 – ₹1,838 · fair‑value band ₹645.21 – ₹2,351 · the ₹1,838 price screens above the ₹860.28 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Inventurus Knowledge Solutions Limited (IKS) currently trades at ₹1,838, while our model-based Fair Value estimate is ₹860.28 — implying the stock looks roughly 53.2% overvalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Inventurus Knowledge Solutions Limited generated revenue of ₹31.9B at a net margin of 22.6%. Revenue grew 18.5% year over year. It earns a return on equity of 31.4%. Net debt stands at ₹3.6B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Inventurus Knowledge Solutions Limited operates as a technology-enabled healthcare solutions provider. The company offers a care enablement platform that assists physician businesses in outpatient and inpatient care activities in the United States, Canada, and Australia. The company offers a platform that serves healthcare organizations, including health systems/ integrated delivery networks, academic medical centers, multi-specialty medical groups, single-specialty medical groups, ancillary healthcare organizations, and other outpatient healthcare delivery organizations. Inventurus Knowledge Solutions Limited was incorporated in 2006 and is based in Navi Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Inventurus Knowledge Solutions Limited reported revenue of ₹31.9B in FY2026 versus ₹7.6B in FY2022, a compound +43.0%/yr. Reported net income was ₹7.2B in FY2026, compounding +32.7%/yr from FY2022.
Is IKS fairly valued? → Check now
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $159.71 | $103.58 | -35% |
| Pro Medicus Limited PME | A$172.80 | A$32.25 | -81% |
| BrightSpring Health Services, Inc BTSG | $67.20 | $26.39 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $89.72 | $54.47 | -39% |
| M3, Inc MTHRY | $5.20 | $5.32 | +2% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Inventurus Knowledge Solutions Limited (IKS) undervalued?
What is the fair value of IKS?
What is the quality score of IKS?
What is the revenue of Inventurus Knowledge Solutions Limited (IKS)?
What is the net profit margin of IKS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.